北京
诺泰生物位于连云港中华药港的口服固体制剂车间，于2023年12月26日顺利投产。
车间按照FDA/EMA标准设计，引进Glatt湿法制粒线、KILIAN双出料压片机、SYNTEGON胶囊填充机、Glatt包衣机、CAM自动化包装线等国际一线品牌设备，设计年产能：片剂&硬胶囊剂45亿片/粒、口服干混悬剂&颗粒剂（瓶装）3600万瓶、颗粒剂（袋装）/散剂4.5亿袋。
车间的顺利投产标志着“诺泰生物新制剂工厂建设项目”Ⅰ期工程圆满完成，将极大提高公司制剂产品的CDMO和生产能力，可为客户为患者提供更多更优质的服务和产品。
Sinopep proudly announces the successfulinauguration of its cutting-edge oral solid dosage facility, strategicallypositioned within Lianyungang's Chinese Pharmaceutical Harbor on December 26,2023, signifying a seamless commencement of operations.
Engineered to meet stringent FDA/EMAstandards, this facility showcases a suite of premier equipment sourced fromglobally acclaimed brands including but not limited to Glatt's wet granulationline, Kilian's tablet press machines, Syntegon's capsule filling machine,Glatt's coating system, and CAM's automatic packaging machines. Its designedannual output boasts remarkable capabilities: 4.5 billion tablets/capsules, 36million bottled oral powders/granules, and 450 million powder/dispersedgranules.
The successful launch of this workshopmarks the triumphant completion of Phase I within the "Sinopep’s NewFormulation Factory Construction Project." This significant milestonesubstantially elevates the company's proficiency in Contract Development andManufacturing Organization (CDMO) service and drug product manufacturing,promising an expanded array of premium services and superior-quality productscatering to both customers and patients.
供稿人：李达 Dr.Qiao
关于诺泰生物
诺泰生物（股票代码：688076）
2009年成立，2021年科创板上市
聚焦多肽药物、小分子化药
战略布局寡核苷酸药物
自主研发和CDMO业务相结合
总部及研究院位于浙江杭州
在连云港市及杭州建德市分别拥有生产基地
中科院专家领衔，海归博士为骨干的研发团队
建有博士后工作站
(诺泰生物)
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
